Xenon Reports Positive Phase 1 and Preclinical Data for Pain Programs
Xenon said Phase 1 and new preclinical data support advancing XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain.
Related stories
Amazon Capex Reaches $77.3 Billion Last Quarter, Above Expectations
Amazon’s capital expenditure rose 43% sequentially and was $20 billion above expectations, according to the report.
H impact | EQUITY | Oct 30, 2026, 05:16 AM UTC
DJT Shares Trade More Than 2% Lower Overnight
Trump Media & Technology Group shares hit an intraday all-time low of $5.68 on Thursday, closing 3% lower and more than 61% below their annual highs. The stock continued to trade m
M impact | EQUITY | Oct 30, 2026, 05:10 AM UTC
4-PAG to Acquire 51% Stake in Evergrande Property Services
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC
PAG to Acquire 51% of Evergrande Property Services
PAG will acquire a 51% stake in Evergrande Property Services.
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC
Proya Shares Hit Limit Down, Fall 8.4% in Morning Trade
China cosmetics maker Proya traded at its daily limit-down level of 48.86 yuan, its lowest since Feb. 4, 2020, before closing the morning session down 8.4%. Citi cut its price targ
M impact | EQUITY | Oct 30, 2026, 04:46 AM UTC
Amazon Shares Fall 6% After Disappointing Wall Street
Amazon shares fell 6%, according to the headline.
M impact | EQUITY | Oct 30, 2026, 04:33 AM UTC